- Home
- ELDN vs CMCM Comparison
ELDN vs CMCM Comparison
Compare ELDN & CMCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELDN
- CMCM
- Stock Information
- Founded
- ELDN 2004
- CMCM 2009
- Country
- ELDN United States
- CMCM China
- Employees
- ELDN N/A
- CMCM N/A
- Industry
- ELDN Biotechnology: Pharmaceutical Preparations
- CMCM Computer Software: Prepackaged Software
- Sector
- ELDN Health Care
- CMCM Technology
- Exchange
- ELDN Nasdaq
- CMCM Nasdaq
- Market Cap
- ELDN 202.4M
- CMCM 196.4M
- IPO Year
- ELDN N/A
- CMCM 2014
- Fundamental
- Price
- ELDN $2.59
- CMCM $7.21
- Analyst Decision
- ELDN Strong Buy
- CMCM
- Analyst Count
- ELDN 2
- CMCM 0
- Target Price
- ELDN $12.50
- CMCM N/A
- AVG Volume (30 Days)
- ELDN 683.9K
- CMCM 35.7K
- Earning Date
- ELDN 08-14-2025
- CMCM 09-11-2025
- Dividend Yield
- ELDN N/A
- CMCM N/A
- EPS Growth
- ELDN N/A
- CMCM N/A
- EPS
- ELDN 0.21
- CMCM N/A
- Revenue
- ELDN N/A
- CMCM $120,663,543.00
- Revenue This Year
- ELDN N/A
- CMCM $14.27
- Revenue Next Year
- ELDN N/A
- CMCM $39.26
- P/E Ratio
- ELDN $12.78
- CMCM N/A
- Revenue Growth
- ELDN N/A
- CMCM 27.02
- 52 Week Low
- ELDN $2.38
- CMCM $3.28
- 52 Week High
- ELDN $5.54
- CMCM $6.77
- Technical
- Relative Strength Index (RSI)
- ELDN 41.11
- CMCM 71.90
- Support Level
- ELDN $2.54
- CMCM $5.81
- Resistance Level
- ELDN $2.84
- CMCM $6.08
- Average True Range (ATR)
- ELDN 0.13
- CMCM 0.42
- MACD
- ELDN 0.03
- CMCM 0.12
- Stochastic Oscillator
- ELDN 22.73
- CMCM 90.95
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.
About CMCM Cheetah Mobile Inc. each representing fifty (50)
Cheetah Mobile Inc along with its subsidiaries provides comprehensive products and services on PCs and mobile devices. It generates revenue from utility-related business, including advertising services and premium membership services. It also provides multi-cloud management platform and overseas advertising agency service. The company operates in two segments: Internet business, and AI and others. The firm's majority of the revenue is derived from the internet business segment that provides mobile advertising services to advertising customers, as well as selling advertisements and referring user traffic on its mobile and PC platforms. Geographically, it derives the majority of its revenue from the PRC and the rest from Hong Kong, Japan, and the rest of the world.